Diversity in Clinical Trials

ENHANCING THE DIVERSITY OF CLINICAL TRIAL POPULATIONS: EMPOWERING DIVERSE PARTICIPATION FOR GLOBALLY RELEVANT OUTCOMES.

The lack of diversity in clinical trials can lead to treatments that are ineffective or even harmful for certain racial and ethnic groups. The Food and Drug Administration (FDA) is pushing for more inclusive trials, but there are historical and logistical barriers to achieving this goal. Brazil, with its rich tapestry of races and ethnicities, offers a unique solution. This diversity closely mirrors a significant portion of the world's population.

Furthermore, data from these trials can provide a more accurate picture of a drug's effectiveness and safety across various populations. This reduces the risk of overlooking potential side effects or inefficacy in specific racial or ethnic groups. By ensuring diverse participation in clinical trials, Brazil can play a vital role in promoting health equity. Drugs designed and tested with a wider range of patients are more likely to benefit a larger portion of the population, reducing health disparities.

CONTACT US TODAY TO DISCUSS YOUR SPECIFIC NEEDS AND UNLOCK THE FULL POTENTIAL OF YOUR TRIAL IN BRAZIL.

Let’s Talk

Schedule with Booking 

YOU CAN SET UP YOUR OWN CALENDAR WITH OUR BOOKING TOOL, AND SCHEDULE APPOINTMENTS TO A RANGE OF DIFFERENT BUSINESS MARKETS.